Acrivon Therapeutics Announces $130 Million Private Placement Financing [Yahoo! Finance]
Acrivon Therapeutics, Inc. (ACRV)
Company Research
Source: Yahoo! Finance
stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced that it has entered into a securities purchase agreement with certain existing and new accredited investors to issue and sell an aggregate of 8,235,000 shares of its common stock at a price of $8.50 per share, a premium to the closing price on April 8, 2024, and pre-funded warrants to purchase up to an aggregate of 7,060,000 shares of common stock at a purchase price of $8.499 per pre-funded warrant, through a private investment in public equity (“PIPE”) financing. The pre-funded warrants will have an exercise price of $0.001 per share of common stock, be immediately exercisable and remain exercisable until exercised in full. Acrivon anticipates the gross proceeds fro
Show less
Read more
Impact Snapshot
Event Time:
ACRV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACRV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACRV alerts
High impacting Acrivon Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ACRV
News
- Acrivon Therapeutics, Inc. (NASDAQ: ACRV) was downgraded by analysts at LADENBURG THALM/SH SH from a "buy" rating to a "neutral" rating.MarketBeat
- Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its price target raised by analysts at BMO Capital Markets from $18.00 to $25.00. They now have an "outperform" rating on the stock.MarketBeat
- Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its price target raised by analysts at JMP Securities from $14.00 to $17.00. They now have a "market outperform" rating on the stock.MarketBeat
- Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its price target raised by analysts at Piper Sandler from $26.00 to $30.00. They now have an "overweight" rating on the stock.MarketBeat
- Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
ACRV
Earnings
- 8/11/23 - Beat
ACRV
Sec Filings
- 4/30/24 - Form EFFECT
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- ACRV's page on the SEC website